Tritrichomoniasis

Tritrichomoniasis is a protozoal infection primarily caused by Tritrichomonas foetus, a flagellated, anaerobic, single-celled parasite that colonizes the large intestine of cats, leading to chronic large-bowel diarrhea. The disease is most commonly recognized in young, purebred cats from high-density environments such as catteries and shelters. The organism is highly species-specific, with feline isolates being genetically distinct from bovine venereal strains. The infection is typically limited to the ileum, cecum, and colon, where it adheres to the mucosal surface and induces a lymphoplasmacytic and neutrophilic inflammatory response. Clinical disease is characterized by chronic, malodorous, semi-formed to liquid feces with increased frequency, tenesmus, and occasional hematochezia. While the infection is often self-limiting in immunocompetent adults, it can persist for months to years, especially in kittens or immunocompromised individuals. The disease is of significant clinical importance due to its high prevalence in multi-cat environments, diagnostic challenges, and the need for specific antiprotozoal therapy.

The primary causative agent is Tritrichomonas foetus, a protozoan parasite belonging to the order Trichomonadida. It is a flagellated, anaerobic organism with three anterior flagella and a single posterior flagellum, which forms an undulating membrane. The trophozoite is the only known life stage; no cyst form has been identified, which is critical for transmission and environmental survival. The organism is transmitted via the fecal-oral route, primarily through direct contact with infected feces or contaminated litter boxes, food bowls, and grooming tools. The parasite is highly susceptible to desiccation and does not survive long outside the host, but it can persist in moist environments for several days. Feline isolates of T. foetus are genetically distinct from bovine venereal strains, and they lack the ability to cause reproductive disease in cattle. The organism colonizes the ileum, cecum, and colon, where it adheres to the mucosal epithelium and multiplies by binary fission. Virulence factors include surface adhesins, cysteine proteases, and the ability to induce apoptosis of epithelial cells, leading to mucosal damage and inflammation. Co-infections with other enteropathogens, such as feline coronavirus, Giardia, or Salmonella, can exacerbate clinical signs.

Tritrichomoniasis is a worldwide disease, with a higher prevalence in areas with dense cat populations, such as catteries, shelters, and multi-cat households. Young cats, particularly those under one year of age, are most commonly affected, with a peak incidence between 3 and 12 months. Purebred cats, including Siamese, Bengal, Abyssinian, and Persian breeds, are overrepresented, likely due to the high-density living conditions and breeding practices in catteries. No sex predilection has been consistently reported. The prevalence in shelter cats can be as high as 30%, while in pet cats with chronic diarrhea, it ranges from 10% to 30%. The organism is transmitted by the fecal-oral route, and the risk of infection increases with poor hygiene, overcrowding, and shared litter boxes. The disease is more common in warm, humid climates, but it can occur in any geographic region. The infection is often subclinical in adult cats, serving as a reservoir for transmission to susceptible kittens. The zoonotic potential is negligible, as feline isolates are not known to infect humans.

The pathophysiology of tritrichomoniasis involves colonization of the distal ileum, cecum, and colon by T. foetus trophozoites. The organism adheres to the mucosal surface via surface adhesins and flagellar motility, causing mechanical disruption of the epithelial barrier. The parasite secretes cysteine proteases that degrade extracellular matrix proteins and induce apoptosis of enterocytes, leading to mucosal erosion and ulceration. This triggers an innate immune response characterized by infiltration of neutrophils, lymphocytes, and plasma cells into the lamina propria. The inflammatory response results in increased mucosal permeability, leading to fluid and electrolyte secretion into the lumen, causing diarrhea. The organism also stimulates a Th1-type immune response, with elevated levels of pro-inflammatory cytokines such as TNF-α and IFN-γ, which further exacerbate tissue damage. Chronic infection leads to lymphoid hyperplasia and fibrosis of the colonic mucosa, perpetuating clinical signs. The diarrhea is typically large-bowel in origin, with increased frequency, tenesmus, and mucus, but the exact mechanisms of altered motility and secretion are not fully understood. The parasite does not invade beyond the mucosa, and systemic dissemination is rare. Co-infections with other enteropathogens can synergistically enhance inflammation and clinical severity.

Intrinsic risk factors include young age (kittens under 1 year), genetic susceptibility in certain breeds (e.g., Siamese, Bengal), and immunosuppression due to concurrent viral infections such as feline leukemia virus (FeLV) or feline immunodeficiency virus (FIV). Extrinsic factors include overcrowding, poor sanitation, shared litter boxes, and high-stress environments such as shelters and catteries. Dietary factors, such as sudden changes in diet or high-carbohydrate diets, may alter the intestinal microbiome and promote colonization. Concurrent gastrointestinal infections, including Giardia, Cryptosporidium, and feline coronavirus, can increase susceptibility and exacerbate clinical signs. The use of immunosuppressive drugs, such as corticosteroids, may also predispose to infection. The lack of a cyst form means that the organism is directly transmitted, so any factor that increases fecal-oral contact, such as inadequate litter box cleaning, is a significant risk factor.

The most common clinical sign is chronic large-bowel diarrhea, characterized by increased frequency of defecation, tenesmus, flatulence, and the passage of semi-formed to liquid feces with mucus and occasionally fresh blood. The feces often have a characteristic foul odor. Affected cats may show perianal inflammation and matting of the hair around the anus. Systemic signs are usually absent; cats remain bright, alert, and maintain a good appetite. Weight loss may occur in severe or prolonged cases, but it is not typical. In some cats, the infection is subclinical, and they serve as carriers. The onset of clinical signs is often gradual, and the diarrhea may be intermittent. In kittens, the diarrhea can be more severe and persistent, leading to dehydration and poor growth. Physical examination is often unremarkable, but palpation of the colon may reveal thickened loops or increased gas. The disease is not associated with fever or vomiting in most cases.

Differential diagnoses for chronic large-bowel diarrhea in cats include: 1) Giardiasis – caused by Giardia duodenalis, which can be differentiated by fecal antigen testing or PCR; clinical signs are similar, but giardiasis is more often associated with small-bowel diarrhea and weight loss. 2) Cryptosporidiosis – caused by Cryptosporidium felis, diagnosed by acid-fast staining or PCR; often seen in immunocompromised cats. 3) Feline coronavirus infection – can cause mild enteritis, but may progress to feline infectious peritonitis (FIP); PCR and serology can help. 4) Inflammatory bowel disease (IBD) – a diagnosis of exclusion, confirmed by intestinal biopsy showing lymphoplasmacytic or eosinophilic infiltrates. 5) Food allergy or dietary intolerance – diagnosed by dietary elimination trials. 6) Intestinal lymphoma – especially in older cats, diagnosed by ultrasound and biopsy. 7) Bacterial enteritis (e.g., Salmonella, Campylobacter) – diagnosed by fecal culture. 8) Chronic pancreatitis – may cause diarrhea, but usually with other signs. 9) Exocrine pancreatic insufficiency – rare in cats, diagnosed by serum TLI. 10) Colonic neoplasia – such as adenocarcinoma, diagnosed by imaging and biopsy. Definitive diagnosis of tritrichomoniasis is made by identifying the organism on fresh fecal smear, culture, or PCR.

The diagnostic approach for suspected tritrichomoniasis begins with a thorough history and physical examination, focusing on the pattern of diarrhea and potential exposure to multi-cat environments. The initial step is to rule out common causes of diarrhea with fecal flotation, direct smear, and antigen testing for Giardia and Cryptosporidium. If these are negative, a fresh fecal smear (within 2 hours of defecation) should be examined microscopically for motile trophozoites. The organism is highly motile and can be seen on a wet mount at 400x magnification. However, the sensitivity of direct smear is low (approximately 50%), so if negative, a fecal culture using a commercial pouch system (e.g., InPouch TF) is recommended. The culture is incubated at 25°C for up to 7 days and examined daily for motile organisms. PCR testing on feces is the most sensitive and specific method, with a sensitivity of over 90%, and can be performed on fresh or frozen feces. PCR is particularly useful in chronic cases where the organism may be shed intermittently. If PCR is not available, a therapeutic trial with an antiprotozoal drug may be considered, but this is not recommended as a sole diagnostic method. In cases where diarrhea persists despite treatment, colonoscopy with mucosal biopsy may be indicated to rule out other causes such as IBD or neoplasia.

Complete blood count (CBC) is typically unremarkable, but may show mild eosinophilia or lymphocytosis in some cases. Serum biochemistry is usually within normal limits, but may reveal mild elevations in globulins due to chronic inflammation. Fecal examination is the key diagnostic test. On a fresh fecal smear, motile trophozoites can be seen; they are pear-shaped, approximately 10-20 μm long, with a characteristic undulating membrane and three anterior flagella. The organism moves in a jerky, spiral pattern. Fecal culture in InPouch TF medium is more sensitive than direct smear. PCR on feces is the gold standard, with high sensitivity and specificity. Fecal antigen tests for Giardia and Cryptosporidium should be performed to rule out co-infections. Fecal flotation may reveal other parasites, but T. foetus trophozoites are not easily identified on flotation due to their fragility. In chronic cases, serum cobalamin (vitamin B12) and folate levels may be measured, as chronic diarrhea can lead to malabsorption, but this is not specific to tritrichomoniasis.

Imaging is not typically necessary for the diagnosis of tritrichomoniasis, but abdominal radiography and ultrasonography may be performed to rule out other causes of chronic diarrhea. Radiographs are usually unremarkable, but may show gas-filled loops of the colon. Ultrasonography may reveal thickening of the colonic wall, increased echogenicity of the mucosa, and loss of normal layering in chronic cases. These findings are non-specific and can be seen in IBD, lymphoma, and other inflammatory conditions. In cases where the diarrhea is refractory to treatment, abdominal ultrasound is recommended to assess for other gastrointestinal diseases. Colonoscopy may be performed to visualize the colonic mucosa and obtain biopsies. Endoscopic findings may include erythema, edema, and increased mucus, but are not specific. Histopathology of colonic biopsies typically shows lymphoplasmacytic and neutrophilic inflammation, with or without eosinophils, and may reveal the presence of trophozoites on the mucosal surface, especially if special stains such as Giemsa or immunohistochemistry are used.

Cytological examination of fresh feces is the most direct method for identifying T. foetus trophozoites. A small amount of feces is mixed with a drop of saline on a glass slide, covered with a coverslip, and examined immediately under a microscope. The trophozoites are motile and can be seen at 400x magnification. They are characterized by their pear shape, undulating membrane, and flagella. In some cases, the organism may be seen on cytological preparations of colonic mucosal brushings obtained during colonoscopy. Histopathological examination of colonic biopsies typically reveals a mild to moderate lymphoplasmacytic and neutrophilic colitis, with occasional eosinophils. The lamina propria is expanded by inflammatory cells, and there may be crypt hyperplasia and goblet cell depletion. Trophozoites may be identified on the mucosal surface or within the crypts, but they are often difficult to see on routine hematoxylin and eosin (H&E) staining. Special stains such as Giemsa, periodic acid-Schiff (PAS), or immunohistochemistry can enhance detection. The presence of the organism on histopathology is diagnostic, but the sensitivity is low, so PCR on tissue is recommended if the diagnosis is suspected.

The treatment of choice for tritrichomoniasis in cats is ronidazole, a nitroimidazole antibiotic with antiprotozoal activity. The recommended dosage is 30 mg/kg orally once daily for 14 days. Ronidazole is not approved for use in cats in many countries, but it is the most effective drug, with a reported efficacy of over 90%. It is important to note that ronidazole is neurotoxic, and signs of toxicity include lethargy, anorexia, ataxia, and seizures. If these signs occur, the drug should be discontinued immediately. Other nitroimidazoles, such as metronidazole, are less effective and are not recommended as first-line therapy. Supportive care includes maintaining hydration, providing a highly digestible diet, and using probiotics to restore the intestinal microbiome. In cases of co-infection with other enteropathogens, appropriate treatment should be instituted. In refractory cases, a second course of ronidazole may be considered, but the risk of neurotoxicity increases. It is also important to treat all cats in the household, as asymptomatic carriers can serve as a source of reinfection. Environmental hygiene, including daily cleaning of litter boxes and disinfection with dilute bleach, is essential to prevent reinfection.

The prognosis for tritrichomoniasis is generally good, with most cats showing clinical improvement within 1-2 weeks of treatment with ronidazole. However, the infection may persist in some cats, and diarrhea can recur, especially if the cat is re-exposed to the organism. The long-term prognosis is excellent, as the infection is rarely life-threatening, and most cats eventually clear the infection, although it may take months. Kittens and immunocompromised cats may have a more prolonged course. The mortality rate is very low, and death is usually due to complications such as severe dehydration or concurrent infections. Negative prognostic indicators include the presence of concurrent diseases, such as FIV or FeLV, and the development of ronidazole toxicity. Response to treatment is typically assessed by resolution of clinical signs, but fecal PCR may remain positive for several weeks after treatment, so it is not recommended to test for cure immediately after therapy.

After completion of ronidazole therapy, cats should be monitored for resolution of diarrhea. A recheck examination is recommended 2-4 weeks after treatment to assess clinical response. If diarrhea persists, a fecal PCR should be performed to determine if the infection has been cleared. If the PCR is positive, a second course of ronidazole may be considered, but the risk of neurotoxicity should be discussed with the owner. In cats that remain asymptomatic but are PCR-positive, treatment may not be necessary, but they should be isolated from susceptible cats. Long-term management includes maintaining good hygiene, reducing stress, and providing a balanced diet. Regular fecal examinations are recommended for cats in multi-cat environments to detect subclinical carriers. If ronidazole toxicity is suspected, the drug should be discontinued, and supportive care should be provided. In cases of chronic diarrhea, additional diagnostics such as colonoscopy and biopsy may be indicated to rule out other causes.

Pearls: 1) Always perform a fresh fecal smear in cats with chronic large-bowel diarrhea, especially if they are young and from a multi-cat environment. 2) PCR is the most sensitive diagnostic test and should be used if the initial smear is negative. 3) Ronidazole is the drug of choice, but it must be compounded by a pharmacy, as it is not commercially available. 4) Treat all cats in the household to prevent reinfection. 5) The organism is fragile, so fecal samples should be kept moist and examined within 2 hours. Pitfalls: 1) Metronidazole is often used but is ineffective against T. foetus and may delay proper treatment. 2) Direct smear has low sensitivity, so a negative result does not rule out infection. 3) Ronidazole can cause neurotoxicity, so owners must be warned about signs of toxicity. 4) Fecal flotation is not useful for detecting T. foetus. 5) Do not use corticosteroids to treat diarrhea without a definitive diagnosis, as they may worsen the infection.

The primary drug protocol for tritrichomoniasis is ronidazole at 30 mg/kg orally once daily for 14 days. Ronidazole is a nitroimidazole antibiotic that is not approved for veterinary use in many countries, but it can be obtained from compounding pharmacies. It is important to use the correct formulation, as the drug is often available as a powder for poultry, which must be compounded into capsules or a liquid suspension. The drug should be given with food to reduce gastrointestinal upset. If neurotoxicity occurs (lethargy, ataxia, seizures), the drug should be discontinued immediately, and supportive care should be provided. Alternative drugs, such as metronidazole (10-25 mg/kg PO q12h), are less effective and are not recommended as first-line therapy. Tinidazole has been used in some cases, but its efficacy is not well established. Supportive therapy includes fluid therapy for dehydration, antiemetics if vomiting occurs (though rare), and probiotics to restore the intestinal flora. In cases of co-infection with Giardia, fenbendazole (50 mg/kg PO q24h for 3-5 days) may be added. It is essential to adjust dosages in cats with hepatic or renal impairment, but no specific guidelines are available for ronidazole; caution is advised.

The evidence for the treatment of tritrichomoniasis is based on several key studies. A landmark study by Gookin et al. (2006) evaluated the efficacy of ronidazole in experimentally infected cats and found that a dosage of 30 mg/kg once daily for 14 days eliminated the infection in 90% of cats, while lower dosages were less effective. Another study by Foster et al. (2004) reported that metronidazole was ineffective in clearing the infection. A more recent study by Xenoulis et al. (2013) confirmed the high sensitivity of PCR for diagnosis and the effectiveness of ronidazole in clinical cases. Consensus guidelines from the American Association of Feline Practitioners (AAFP) and the International Society of Feline Medicine (ISFM) recommend ronidazole as the first-line treatment. The use of probiotics has been suggested to reduce the duration of diarrhea, but evidence is limited. Overall, the literature supports the use of ronidazole as the treatment of choice, with a good prognosis for recovery, but emphasizes the importance of accurate diagnosis and monitoring for adverse effects.